Skip to main content
SpringerLink
Log in

Impact of Successful Implementation of an Enhanced Recovery After Surgery Protocol for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are complex operations for the treatment of peritoneal metastases. Enhanced recovery after surgery (ERAS) protocols are intended to standardize preoperative, intraoperative, and postoperative pathways, with the goal of improving patient care. This study describes feasibility and outcomes after implementing an ERAS protocol for CRS/HIPEC at a tertiary academic center.

Methods

A single-institution experience of CRS/HIPEC was reviewed from January 2020 to March 2023. Patients were categorized according to whether they underwent CRS/HIPEC before or after ERAS initiation. Outcomes and protocol adherence were evaluated.

Results

A total of 115 CRS/HIPEC operations were included—74 before and 41 after ERAS implementation. Median age was younger in the post-ERAS group, whereas sex, comorbidities, peritoneal carcinomatosis index, operation performed, and operative time were similar between groups. The most common primary cancer sites were gynecologic (40%), appendiceal (24%), and colorectal (22%). Adherence to all postoperative ERAS components was 76%. More post-ERAS patients ambulated by postoperative day (POD) 1 (90% vs. 54%; p < 0.001), tolerated liquid diet by POD 2 (88% vs. 32%; p < 0.001), and had foley removed by POD 3 (86% vs. 43%; p < 0.001). There was a trend toward decreased length of stay in the post-ERAS cohort (7 vs. 8 days; p = 0.092), with no difference in major complications, intensive care unit admission, or 30-day readmission.

Conclusions

Despite the heterogeneity of CRS/HIPEC operations, implementing an ERAS protocol for our patients was feasible and resulted in postoperative outcomes and adherence comparable with that of other major abdominal surgeries. This supports the potential for success in ERAS programs for CRS/HIPEC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Van Stein RM, Aalbers AGJ, Sonke GS, Van Driel WJ. Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review. JAMA Oncol. 2021;7(8):1231. https://doi.org/10.1001/jamaoncol.2021.0580.

    Article  PubMed  Google Scholar 

  2. Valenzuela CD, Levine EA, Mangieri CW, et al. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for cancers with peritoneal metastasis: a 30-year institutional experience. Ann Surg Oncol. 2022;29(6):3436–45. https://doi.org/10.1245/s10434-022-11441-3.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363. https://doi.org/10.1001/jamasurg.2020.6363.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028–40. https://doi.org/10.1200/JCO.18.01688.

    Article  CAS  PubMed  Google Scholar 

  5. Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.

    Article  PubMed  Google Scholar 

  6. Díaz-Montes TP, El-Sharkawy F, Lynam S, et al. Efficacy of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in the treatment of recurrent uterine sarcoma. Int J Gynecol Cancer. 2018;28(6):1130–7. https://doi.org/10.1097/IGC.0000000000001289.

    Article  PubMed  Google Scholar 

  7. Enomoto LM, Shen P, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. Cancer Manag Res. 2019;11:4231–41. https://doi.org/10.2147/CMAR.S170300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Huffman OG, Chau DB, Dinicu AI, DeBernardo R, Reizes O. Mechanistic insights on hyperthermic intraperitoneal chemotherapy in ovarian cancer. Cancers (Basel). 2023;15(5):1402. https://doi.org/10.3390/cancers15051402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Somashekhar SP, Yethadka R, Kumar CR, Ashwin KR, Zaveri S, Rauthan A. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. Eur J Surg Oncol. 2020;46(4):577–81. https://doi.org/10.1016/j.ejso.2019.10.032.

    Article  CAS  PubMed  Google Scholar 

  10. Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer. 2020;127:76–95. https://doi.org/10.1016/j.ejca.2019.10.034.

    Article  PubMed  Google Scholar 

  11. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790–6. https://doi.org/10.1007/s10434-999-0790-0.

    Article  CAS  PubMed  Google Scholar 

  12. Cooksley TJ, Haji-Michael P. Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). World J Surg Oncol. 2011;9(1):169. https://doi.org/10.1186/1477-7819-9-169.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10(8):863–9. https://doi.org/10.1245/ASO.2003.01.018.

    Article  CAS  PubMed  Google Scholar 

  14. Gani F, Conca-Cheng AM, Nettles B, Ahuja N, Johnston FM. Trends in outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Res. 2019;234:240–8. https://doi.org/10.1016/j.jss.2018.09.032.

    Article  PubMed  Google Scholar 

  15. Jafari MD, Halabi WJ, Stamos MJ, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 2014;149(2):170–5. https://doi.org/10.1001/jamasurg.2013.3640.

    Article  PubMed  Google Scholar 

  16. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900–7. https://doi.org/10.1097/SLA.0b013e3181a45d86.

    Article  PubMed  Google Scholar 

  17. Foster JM, Sleightholm R, Patel A, et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open. 2019;2(1):e186847. https://doi.org/10.1001/jamanetworkopen.2018.6847.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152(3):292. https://doi.org/10.1001/jamasurg.2016.4952.

    Article  PubMed  Google Scholar 

  19. Brindle M, Nelson G, Lobo DN, Ljungqvist O, Gustafsson UO. Recommendations from the ERAS® Society for standards for the development of enhanced recovery after surgery guidelines. BJS Open. 2020;4(1):157–63. https://doi.org/10.1002/bjs5.50238.

    Article  CAS  PubMed  Google Scholar 

  20. the impact of enhanced recovery protocol compliance on elective colorectal cancer resection: results from an international registry. Ann Surg. 2015;261(6):1153-1159. doi:https://doi.org/10.1097/SLA.0000000000001029

  21. Song W, Wang K, Zhang R, Dai Q, Zou S. The enhanced recovery after surgery (ERAS) program in liver surgery: a meta-analysis of randomized controlled trials. Springerplus. 2016;5:207. https://doi.org/10.1186/s40064-016-1793-5.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Wijk L, Udumyan R, Pache B, et al. International validation of enhanced recovery after surgery society guidelines on enhanced recovery for gynecologic surgery. Am J Obst Gynecol. 2019;221(3):237.e1-11. https://doi.org/10.1016/j.ajog.2019.04.028.

    Article  Google Scholar 

  23. Stowers MDJ, Manuopangai L, Hill AG, Gray JR, Coleman B, Munro JT. Enhanced recovery after surgery in elective hip and knee arthroplasty reduces length of hospital stay. ANZ J Surg. 2016;86(6):475–9. https://doi.org/10.1111/ans.13538.

    Article  PubMed  Google Scholar 

  24. Chicago Consensus Working Group, Plana A, Izquierdo FJ, et al. The chicago consensus on peritoneal surface malignancies: standards. Cancer. 2020;126(11):2516-2524. https://doi.org/10.1002/cncr.32825

  25. Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) society recommendations – part i: preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292–310. https://doi.org/10.1016/j.ejso.2020.07.041.

    Article  PubMed  Google Scholar 

  26. Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations – Part II: Postoperative management and special considerations. Eur J Surg Oncol. 2020;46(12):2311–23. https://doi.org/10.1016/j.ejso.2020.08.006.

    Article  PubMed  Google Scholar 

  27. Eng OS, Blakely AM, Lafaro KJ, et al. Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. J Surg Oncol. 2020;122(5):980–5. https://doi.org/10.1002/jso.26099.

    Article  PubMed  Google Scholar 

  28. Maciver AH, Al-Sukhni E, Esquivel J, Skitzki JJ, Kane JM, Francescutti VA. Current delivery of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (CS/HIPEC) and perioperative practices: an international survey of high-volume surgeons. Ann Surg Oncol. 2017;24(4):923–30. https://doi.org/10.1245/s10434-016-5692-3.

    Article  PubMed  Google Scholar 

  29. Dhiman A, Fenton E, Whitridge J, et al. Guide to enhanced recovery for cancer patients undergoing surgery: ERAS for patients undergoing cytoreductive surgery with or without HIPEC. Ann Surg Oncol. 2021;28(12):6955–64. https://doi.org/10.1245/s10434-021-09973-1.

    Article  PubMed  Google Scholar 

  30. Bakker N, Cakir H, Doodeman HJ, Houdijk APJ. Eight years of experience with enhanced recovery after surgery in patients with colon cancer: Impact of measures to improve adherence. Surgery. 2015;157(6):1130–6. https://doi.org/10.1016/j.surg.2015.01.016.

    Article  PubMed  Google Scholar 

  31. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New Engl J Med. 2002;346(13):975–80. https://doi.org/10.1056/NEJMoa012385.

    Article  CAS  PubMed  Google Scholar 

  32. Laplace N, Kepenekian V, Friggeri A, et al. Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin. Int J Hyperthermia. 2020;37(1):897–902. https://doi.org/10.1080/02656736.2020.1795277.

    Article  CAS  PubMed  Google Scholar 

  33. Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14(1):128. https://doi.org/10.1186/s12957-016-0892-7.

    Article  PubMed  PubMed Central  Google Scholar 

  34. White B, Dahdaleh F, Naffouje SA, et al. Impact of enhanced recovery after surgery on postoperative outcomes for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2021;28(9):5265–72. https://doi.org/10.1245/s10434-020-09476-5.

    Article  PubMed  Google Scholar 

  35. Lu PW, Fields AC, Shabat G, et al. Cytoreductive surgery and HIPEC in an enhanced recovery after surgery program: a feasibility study. J Surg Res. 2020;247:59–65. https://doi.org/10.1016/j.jss.2019.10.042.

    Article  PubMed  Google Scholar 

  36. Siddharthan R, Dewey E, Billingsley K, Gilbert E, Tsikitis VL. Feasibility and benefits of an enhanced recovery after surgery protocol for patients undergoing cytoreductive surgery and heated intraperitoneal chemotharpy: a single institution experience. Am J Surg. 2020;219(6):1073–5. https://doi.org/10.1016/j.amjsurg.2019.06.019.

    Article  PubMed  Google Scholar 

  37. Duzgun O. Evaluation of enhanced recovery after following a surgical protocol for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Med Arch. 2019;73(5):331. https://doi.org/10.5455/medarh.2019.73.331-337.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Webb C, Day R, Velazco CS, et al. Implementation of an enhanced recovery after surgery (ERAS) program is associated with improved outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2020;27(1):303–12. https://doi.org/10.1245/s10434-019-07900-z.

    Article  PubMed  Google Scholar 

  39. Charleux-Muller D, Fabacher T, Romain B, Meyer N, Brigand C, Delhorme JB. Implementation of an enhanced recovery program for complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a referral center: a case control prospective study. Pleura and Peritoneum. 2023;8(1):11–8. https://doi.org/10.1515/pp-2022-0133.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66. https://doi.org/10.1016/S1470-2045(20)30599-4.

    Article  PubMed  Google Scholar 

  41. Elgendy H, Iqbal M, Youssef T, Alzahrani A, Rugaan A. Optimizing risk factors influence intensive care stay after hyperthermic intraperitoneal chemotherapy? an observational cohort study. Cancer Treatment Res Commun. 2022;33:100653. https://doi.org/10.1016/j.ctarc.2022.100653.

    Article  Google Scholar 

  42. Salenger R, Morton-Bailey V, Grant M, Gregory A, Williams JB, Engelman DT. Cardiac enhanced recovery after surgery: a guide to team building and successful implementation. Sem Thoracic Cardiovasc Surg. 2020;32(2):187–96. https://doi.org/10.1053/j.semtcvs.2020.02.029.

    Article  Google Scholar 

  43. Liu JY, Wick EC. Enhanced recovery after surgery and effects on quality metrics. Surg Clin North America. 2018;98(6):1119–27. https://doi.org/10.1016/j.suc.2018.07.001.

    Article  Google Scholar 

  44. Gustafsson UO. Adherence to the enhanced recovery after surgery protocol and outcomes after colorectal cancer surgery. Arch Surg. 2011;146(5):571. https://doi.org/10.1001/archsurg.2010.309.

    Article  PubMed  Google Scholar 

  45. Ahmed J, Khan S, Lim M, Chandrasekaran TV, MacFie J. Enhanced recovery after surgery protocols – compliance and variations in practice during routine colorectal surgery. Colorectal Disease. 2012;14(9):1045–51. https://doi.org/10.1111/j.1463-1318.2011.02856.x.

    Article  CAS  PubMed  Google Scholar 

  46. Gustafsson UO, Oppelstrup H, Thorell A, Nygren J, Ljungqvist O. Adherence to the ERAS protocol is Associated with 5-Year survival after colorectal cancer surgery: a retrospective cohort study. World J Surg. 2016;40(7):1741–7. https://doi.org/10.1007/s00268-016-3460-y.

    Article  PubMed  Google Scholar 

  47. Ripollés-Melchor J, Ramírez-Rodríguez JM, Casans-Francés R, et al. Association between use of enhanced recovery after surgery protocol and postoperative complications in colorectal surgery: the postoperative outcomes within enhanced recovery after surgery Protocol (POWER) Study. JAMA Surg. 2019;154(8):725–36. https://doi.org/10.1001/jamasurg.2019.0995.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Feng J, Li K, Xu R, et al. Association between compliance with enhanced recovery after surgery (ERAS) protocols and postoperative outcome in patients with primary liver cancer undergoing hepatic resection. J Cancer Res Clin Oncol. 2022;148(11):3047–59. https://doi.org/10.1007/s00432-021-03891-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Schmelzle M, Krenzien F, Dahlke P, et al. Validation of the enhanced recovery after surgery (ERAS) society recommendations for liver surgery: a prospective, observational study. Hepatobiliary Surg Nutr. 2023;12(1):20–36. https://doi.org/10.21037/hbsn-21-294.

    Article  PubMed  Google Scholar 

  50. Roulin D, Melloul E, Wellg BE, et al. Feasibility of an enhanced recovery protocol for elective pancreatoduodenectomy: a multicenter international cohort study. World J Surg. 2020;44(8):2761–9. https://doi.org/10.1007/s00268-020-05499-x.

    Article  PubMed  Google Scholar 

  51. Robertson N, Gallacher PJ, Peel N, et al. Implementation of an enhanced recovery programme following pancreaticoduodenectomy. HPB. 2012;14(10):700–8. https://doi.org/10.1111/j.1477-2574.2012.00521.x.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Braga M, Pecorelli N, Ariotti R, et al. Enhanced recovery after surgery pathway in patients undergoing pancreaticoduodenectomy. World J Surg. 2014;38(11):2960–6. https://doi.org/10.1007/s00268-014-2653-5.

    Article  PubMed  Google Scholar 

  53. Pisarska M, Pędziwiatr M, Małczak P, et al. Do we really need the full compliance with ERAS protocol in laparoscopic colorectal surgery? A prospective cohort study. Int J Surg. 2016;36:377–82. https://doi.org/10.1016/j.ijsu.2016.11.088.

    Article  PubMed  Google Scholar 

  54. Roulin D, Muradbegovic M, Addor V, Blanc C, Demartines N, Hübner M. Enhanced recovery after elective colorectal surgery – reasons for non-compliance with the protocol. Dig Surg. 2017;34(3):220–6. https://doi.org/10.1159/000450685.

    Article  PubMed  Google Scholar 

  55. Philip J, Fairtile R, Cocieru A. Postoperative complications are main reason for noncompliance with enhanced recovery after surgery program in patients undergoing hepatectomy and pancreatectomy. JGH Open. 2020;4(2):236–40. https://doi.org/10.1002/jgh3.12250.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Section of Surgical Oncology, Stanford University School of Medicine, Stanford, CA, USA

    Beatrice J. Sun MD & Byrne Lee MD

  2. Stanford University School of Medicine, Stanford, CA, USA

    Tiffany M. Yue BA & Nova Xu BS

  3. Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, USA

    Cedar Fowler MD, PhD

Authors
  1. Beatrice J. Sun MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tiffany M. Yue BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nova Xu BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cedar Fowler MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Byrne Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Byrne Lee MD.

Ethics declarations

Disclosure

Beatrice J. Sun, Tiffany M. Yue, Nova Xu, Cedar Fowler, and Byrne Lee have no disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sun, B.J., Yue, T.M., Xu, N. et al. Impact of Successful Implementation of an Enhanced Recovery After Surgery Protocol for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 30, 8156–8165 (2023). https://doi.org/10.1245/s10434-023-14222-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-14222-8

Search

Navigation